The significant reduction in prostate weight observed after ATGSE treatment correlates closely with the decrease in PSA levels, indicating the efficacy of the treatment in reducing prostate hyperplasia and restoring physiological prostate volume. The gene discussed is KLK3; the disease is benign prostatic hyperplasia.